tirzepatide · Eli Lilly
What should I know about Mounjaro?
Mounjaro by Eli Lilly: Type 2 diabetes. Cost, side effects, dosing as labeled, comparisons and the latest news, all sourced.
Start hereMounjaro FAQ: Approved Uses, Dosing, Cost, and RisksMounjaro (tirzepatide) is FDA-approved to improve blood sugar in adults and children 10+ with type 2 diabetes and to reduce major cardiovascular events in high-risk adults. The list price is $1,112.16 per monthly fill; LillyDirect self-pay starts at $499/month.
Medications
GLP-1 Drugs Ranked by Effectiveness: Weight and A1C ResultsTirzepatide ranks first on both scoreboards: -20.9% body weight in SURMOUNT-1 and a 2.30-point A1C drop that beat semaglutide head to head. Injectable semaglutide is second, the orforglipron pill third on weight, liraglutide fourth. Direct trials back the top spots; the heart-protection scoreboard reshuffles the order.Mounjaro vs Zepbound: Same Drug, Different Approved UsesMounjaro and Zepbound are both tirzepatide injections made by Eli Lilly, approved under separate FDA applications: Mounjaro for type 2 diabetes and cardiovascular risk, Zepbound for weight management and obstructive sleep apnea.Ozempic vs Mounjaro: Differences, Dosing, and Which Is Better for Type 2 DiabetesOzempic (semaglutide) and Mounjaro (tirzepatide) are both once-weekly type 2 diabetes injections, but they are different molecules from different makers. In SURPASS-2, tirzepatide beat injectable semaglutide on A1C and weight, while only Ozempic carries a chronic kidney disease indication.Zepbound Doses List vs. Mounjaro: Every Pen and Vial StrengthZepbound and Mounjaro both come in six tirzepatide strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Each strength exists as a single-dose pen or vial (0.5 mL per dose) and as a multi-dose vial or KwikPen holding 2.4 mL, which is four weekly 0.6 mL doses.
GLP-1 culture
Celebrities on Mounjaro and Zepbound: Who Said WhatFour public figures have named Mounjaro or Zepbound themselves: Shaquille O'Neal with Zepbound, and Whoopi Goldberg, Sunny Hostin and Tori Spelling with Mounjaro. Serena Williams disclosed GLP-1 treatment without naming a brand, and several disclosures are paid corporate campaign partnerships.How Many Americans Take Zepbound? What the Published Numbers ShowNo official count of US Zepbound users has been published. What exists is Lilly's audited revenue: Zepbound made $13,542 million in 2025, up 175%, and Lilly says it was the most prescribed weight management medication that year.
Cost
Cheapest Way to Get Tirzepatide Legally: 2026 PricesThe cheapest legal route depends on coverage: $25 for up to 3 months with a commercial plan that covers the drug, $50 per month through Medicare's GLP-1 Bridge starting July 1, 2026, near-zero on Medicaid in 13 states, or $299–$449 per month self-pay for the Zepbound KwikPen or vial.Does Medicare Cover Zepbound? Routes, Costs, and the $50 BridgeMedicare won't pay for Zepbound or Mounjaro for weight loss alone. Two routes exist: the GLP-1 Bridge at $50 per month (July 1, 2026–December 31, 2027, Zepbound KwikPen only) and regular Part D coverage for diabetes, sleep apnea, or fatty liver disease. Without coverage, the manufacturer discount price is $299.00.How Much Does Mounjaro Cost? Prices With and Without Insurance (2026)Mounjaro's list price is $1,112.16 per fill (four pens, one month), LillyDirect self-pay starts at $499/month, and commercially insured patients whose plan covers Mounjaro can pay as little as $25 for up to a 3-month prescription with the savings card.Zepbound Savings Card: What You Pay and Who QualifiesThe Zepbound savings card can drop the cost to as little as $25 for a 1- to 3-month fill of the single-dose pen if your commercial insurance covers it, with savings capped at $1,300 per year. A separate KwikPen self-pay card offers cash prices from $299 a month.
Compounded
Compounded Tirzepatide: What It Is and Whether It's Legal in 2026Compounded tirzepatide is a copy of the active ingredient in Mounjaro and Zepbound made by a pharmacy, not a generic and not FDA-reviewed. Mass compounding became unlawful after the FDA declared the shortage resolved on December 19, 2024, with enforcement deadlines passing in February and March 2025.How to Spot Fake Mounjaro or Zepbound: Warning Signs to CheckThe safest test is where it came from: Lilly is the only lawful supplier of FDA-approved tirzepatide and never sells on social media. FDA has received more than 730 adverse event reports tied to compounded tirzepatide, and one Tennessee raid seized more than 300 counterfeit vials.
Side effects
Does Zepbound Cause Hair Loss? What the Label and Studies ShowHair loss is a listed adverse reaction on the Zepbound label, reported by 4–5% of patients in trials versus 1% on placebo, mostly women, and the label ties it to weight reduction. Causality has not been established.Mounjaro Lawsuits: What's Alleged and Where Cases Stand in 2026Mounjaro is named in MDL 3094, the federal GLP-1 gastrointestinal injury litigation, and Zepbound is among Lilly's medicines at issue per its May 2026 brief. Nearly 3,000 gastroparesis suits were pending as of December 2025; a Daubert hearing was set for September 14–18, 2026.Mounjaro Side Effects: What the Label Reports and How OftenThe most common Mounjaro side effects are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain; nausea reached 18% at the 15 mg dose in placebo-controlled trials. The label also carries a boxed warning about thyroid C-cell tumors seen in rats.Tirzepatide vs Semaglutide Side Effects: What Direct Comparison ShowsSURMOUNT-5 (751 adults) found mostly mild-to-moderate GI side effects in both arms; a 46,620-pair real-world study found an HR of 1.07 for serious GI events with tirzepatide vs semaglutide. Label percentages cannot be compared across drugs.Zepbound and Alcohol: Label Warnings and Drinking EvidenceThe Zepbound and Mounjaro Drug Interactions sections cover insulin, sulfonylureas, and oral medications. A study of more than 120 million US health records linked tirzepatide to about half the rate of new alcohol use disorder diagnoses (HR 0.47), and a 42-person randomized trial is underway.
News timeline
Eli Lilly GLP-1 News 2026: The Biggest Stories Through Mid-SeptemberEli Lilly's 2026 so far: FDA approval of the oral GLP-1 pill Foundayo on April 1, 2026, a cardiovascular approval for Mounjaro, record retatrutide weight loss of 70.3 lbs (28.3%), and a false-advertising lawsuit from Novo Nordisk filed July 21.Tirzepatide History: Mounjaro and Zepbound Year by YearTirzepatide reached the U.S. market as Mounjaro for type 2 diabetes on May 13, 2022, then as Zepbound for weight management on November 8, 2023. Trial weight loss ran from 15.7% in people with diabetes to 22.5% in SURMOUNT-1, and a 2024 head-to-head trial showed 20.2% for Zepbound vs. 13.7% for Wegovy.Zepbound News 2025: The Biggest Stories on Price, Coverage and CompetitionIn 2025, Zepbound and Mounjaro news shifted from shortages to money: Medicare opened limited coverage, CVS dropped Zepbound from its biggest formularies, and Lilly cut cash vial prices to $299–$449 per month by December.
Who they're for
GLP-1 and Men's Health: Testosterone, Erections, Sperm and MusclePost hoc analyses reported in a conference abstract suggest women lose about 40% more weight than men on GLP-1 drugs. A review of five trials found no negative impact on hormones, sexual function or sperm quality, with possible testosterone gains for men whose low T is driven by obesity [1][10].GLP-1 for Teens: Which Drugs Are Approved and What Studies ShowOnly Wegovy injection (ages 12+) and Saxenda (ages 12+ with body weight over 60 kg) carry a teen weight-loss indication. Mounjaro is labeled for ages 10 and older only for type 2 diabetes, not weight loss. Zepbound is adults-only.GLP-1 for Type 1 Diabetes: What the Research Actually ShowsNo GLP-1 drug is FDA-approved for type 1 diabetes. One small randomized trial found 36% of adults on semaglutide hit a combined glucose-and-weight goal versus 0% on placebo, with weight 8.8 kg lower than placebo at 26 weeks.Who Should Not Take GLP-1 Drugs: Contraindications and WarningsOnly two things rule out these drugs outright: a personal or family history of medullary thyroid carcinoma or MEN 2, and hypersensitivity to the drug or its ingredients (Wegovy's label says "known" hypersensitivity; the other three say "serious"). Everything else is a warning or "not recommended."
Results
GLP-1 Plateau: Why Weight Loss Stalls on Wegovy and ZepboundYes — a stall is a normal part of treatment. In tirzepatide trials, the median time to a weight plateau was 24.3 to 36.1 weeks depending on starting BMI, and about 90% of participants had plateaued by week 72.How Fast Does Zepbound Work? Timeline of Weight Loss ResultsZepbound's biggest share of loss came in the first 24 weeks — about 13.3% to 14.5% among adherent trial participants who lost at least 5% — with a plateau typically at 24 to 36 weeks and 72-week label averages of 15.0% to 20.9% depending on dose.
How it works
How Does Mounjaro Work? Mechanism, Dosing, and Ozempic ComparisonMounjaro (tirzepatide) is a once-weekly injection that activates two gut-hormone receptors, GIP and GLP-1, while drugs like Ozempic act on GLP-1 alone. Through GLP-1 signaling it stimulates insulin release, suppresses glucagon, slows the stomach, and cuts appetite; its half-life is about 5 days.How Long Does Tirzepatide Stay in Your System? (Mounjaro, Zepbound)Tirzepatide has a half-life of about 5 days, so after your last weekly shot the drug keeps working its way out of your blood for roughly 25 days — about five half-lives. Here's what the labels and FDA review actually say.Semaglutide vs Tirzepatide: Which Works Better for Weight Loss?Semaglutide (Ozempic, Wegovy) targets one receptor; tirzepatide (Mounjaro) targets two. In the only head-to-head trial, tirzepatide produced −20.2% body weight vs −13.7% for semaglutide at 72 weeks.Tirzepatide and Birth Control: Does It Affect the Pill?Yes — the Mounjaro and Zepbound labels say tirzepatide can affect absorption of oral contraceptives, and advise switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase.
FDA and regulation
Is Tirzepatide Still in Shortage? FDA Status and TimelineNo. Tirzepatide injection (Mounjaro, Zepbound) came off the FDA drug shortage list on October 2, 2024, and FDA re-confirmed that decision on December 19, 2024. An appeals court upheld the removal on August 27, 2026.Tirzepatide Approvals by Country: Mounjaro and Zepbound WorldwideTirzepatide is approved for type 2 diabetes and weight management in the US, EU, UK, Canada, Australia, Japan, China and India. The US approved Mounjaro for diabetes on May 13, 2022 and sells the weight-loss version as Zepbound; the UK and Europe use the Mounjaro name for both uses.Tirzepatide FDA Approval History: Mounjaro and Zepbound, Year by YearThe FDA approved tirzepatide as Mounjaro (NDA 215866) on May 13, 2022 for type 2 diabetes and as Zepbound (NDA 217806) on November 8, 2023 for weight management. Later approvals added sleep apnea (December 20, 2024), pediatric diabetes (December 19, 2025), and cardiovascular risk reduction (August 27, 2026).
Emerging uses
Microdosing Zepbound: What the Evidence Actually ShowsMicrodosing Zepbound has no clinical definition, and clinicians say there is no robust evidence it works at very small doses. The label approves 5, 10, or 15 mg weekly for maintenance, and SURMOUNT-MAINTAIN found 5 mg held weight loss at −16.6% versus −9.9% for placebo.Tirzepatide for PCOS: Evidence, Approval, and Pregnancy RisksTirzepatide (Mounjaro/Zepbound) is not FDA-approved for PCOS. One small 16-week trial found 10.4 kg weight loss and 53.6% menstrual recovery when added to metformin, but a larger placebo-controlled trial is still recruiting.What Else Can Tirzepatide Treat? Approved and Studied UsesTirzepatide (Mounjaro, Zepbound) is FDA-approved for type 2 diabetes, weight loss, sleep apnea, and — since August 2026 — reducing heart attack and stroke risk in adults with diabetes at high risk. Heart failure, diabetes prevention, and fatty liver show positive trials but no approval.
How to use
Common questions
Alternatives
Trial evidence
Semaglutide vs Tirzepatide: Which Is Better for Weight Loss? SURMOUNT-5 ExplainedIn the first published head-to-head randomized trial in adults with obesity without diabetes, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide over 72 weeks. Here is what the study showed, plus side effects, heart evidence, and how clinicians say to choose.Tirzepatide Clinical Trial Results: What the Studies ShowIn phase 3 trials, tirzepatide produced 15.0–20.9% mean weight loss over 72 weeks in adults with obesity (vs 3.1% on placebo) and cut HbA1c by 1.87–2.8 points across the diabetes trials, beating semaglutide 1 mg and two insulins head to head. Heart, kidney, and liver trial results were not verified for this page.